Botanix Financial Statements From 2010 to 2025
| BXPHF Stock | USD 0.08 0.00 0.00% |
Check Botanix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Botanix Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Botanix financial statements analysis is a perfect complement when working with Botanix Pharmaceuticals Valuation or Volatility modules.
Botanix |
Botanix Pharmaceuticals Limited Company Current Valuation Analysis
Botanix Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Botanix Pharmaceuticals Current Valuation | 43.12 M |
Most of Botanix Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Botanix Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Botanix Pharmaceuticals Limited has a Current Valuation of 43.12 M. This is 99.7% lower than that of the Healthcare sector and 99.07% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.74% higher than that of the company.
Botanix Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Botanix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Botanix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Botanix Pharmaceuticals competition to find correlations between indicators driving Botanix Pharmaceuticals's intrinsic value. More Info.Botanix Pharmaceuticals Limited is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Botanix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Botanix Pharmaceuticals Financial Statements
Botanix Pharmaceuticals stakeholders use historical fundamental indicators, such as Botanix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Botanix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Botanix Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Botanix Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Botanix Pharmaceuticals Limited. Please read more on our technical analysis and fundamental analysis pages.
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company was incorporated in 1984 and is based in Leederville, Australia. Botanix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Botanix Pink Sheet
Botanix Pharmaceuticals financial ratios help investors to determine whether Botanix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Botanix with respect to the benefits of owning Botanix Pharmaceuticals security.